160 related articles for article (PubMed ID: 22215850)
41. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
[TBL] [Abstract][Full Text] [Related]
42. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
43. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
44. The great biomarker chase.
Mortkowitz L
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP22-3. PubMed ID: 22468869
[No Abstract] [Full Text] [Related]
45. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
46. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
47. New therapy targets resistant non-small-cell lung cancers.
Jenks S
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
[No Abstract] [Full Text] [Related]
48. Trial offers early test case for personalized medicine.
Garber K
J Natl Cancer Inst; 2009 Feb; 101(3):136-8. PubMed ID: 19176464
[No Abstract] [Full Text] [Related]
49. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
50. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
[No Abstract] [Full Text] [Related]
51. For EGFR research, new targeted drugs mean new questions.
Vastag B
J Natl Cancer Inst; 2005 May; 97(9):628-30. PubMed ID: 15870431
[No Abstract] [Full Text] [Related]
52. The potential for targeting the STAT3 pathway as a novel therapy for melanoma.
Lesinski GB
Future Oncol; 2013 Jul; 9(7):925-7. PubMed ID: 23837753
[No Abstract] [Full Text] [Related]
53. Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer.
Qi X; Ma W; Li S; Zhou C
Lung Cancer; 2014 Aug; 85(2):335-6. PubMed ID: 24854402
[No Abstract] [Full Text] [Related]
54. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
55. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
56. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067
[TBL] [Abstract][Full Text] [Related]
57. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
58. Gefitinib versus cetuximab in lung cancer: round one.
Minna JD; Peyton MJ; Gazdar AF
J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
[No Abstract] [Full Text] [Related]
59. Selection bias, phase II trials, and the FDA accelerated approval process.
George SL
J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
[No Abstract] [Full Text] [Related]
60. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
